Laverock Therapeutics develops advanced therapies by reprogramming the cell's own gene control systems. The company uses technology that harnesses naturally-occurring microRNAs (miRNAs) to conditionally silence genes in a programmable, tunable, stable, and specific manner.

Laverock Therapeutics

Next generation programmable cell therapies

We are proud to have been selected as a finalist in this year’s Business Weekly newspaper Awards. 

2023 was transformational year for Laverock Therapeutics and saw us take significant steps in advancing our technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of more effective, safer and accessible programmable advanced therapies. We raised the second largest UK life sciences seed round of 2023, £13.5 million and grew our team by more than 50% in the past year.

The awards cover companies from across the whole of the East of England including Stevenage Bioscience Catalyst, and across sectors including #biotech so we know competition will be fierce. We congratulate all the finalists. https://lnkd.in/ejim8hvh

Tony Quested, Editor said, ‘The competition has attracted a record entry in terms of numbers and the quality throughout the shortlist is also arguably the best we have ever seen.’

Winners will be announced during at a dinner at Queens’ College on September 11. 

#innovation #award #finalist #AdvancedTherapies

Are you ready to take the next step in your scientific career? Laverock Therapeutics is looking for passionate and driven individuals to join our innovative team.

If you’re ready to make a difference and be part of something extraordinary, we want to hear from you.

Apply now and embark on an exciting journey with Laverock Therapeutics!
#Careers #JobOpening #ScientificJobs #LaverockTherapeutics #JoinOurTeam

https://lnkd.in/emdgFBkg

Could you be our next star Scientist? Come and join the team :)

As one of the innovative companies in the Stevenage Bioscience Catalyst Incubator, we were delighted to see Labour choose the site to launch its Life Sciences Industry Strategy. 
 
We are driving the development of a new generation of effective, safe and accessible advanced therapies to tackle major diseases based on our novel and uniquely powerful gene-silencing technology.
 
#innovation

Developer of a unique gene silencing platform Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by @UKI2S.  

https://lnkd.in/ezutNAaw

Metric
Company Name	Laverock Therapeutics
Symbol
MSH ID	COM:LAVEROCKTX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	34
Website	laverocktx.com
LinkedIn	laverock-tx
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:LAVEROCKTX

Laverock Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue